Reference No: MAR0511Pages: 21Published on: 31, January, 2020
Abstract: Lupin, an India-based pharma firm, started its Novel Drug Discovery and Development (NDDD) division in 2010. In 2018, the division licensed MALT1 inhibitors to AbbVie, an MNC Pharma firm for a down payment of USD 30 million, to be followed by progressive payments of USD 947 million over 10 years. This was the first success ... More